Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST)

Addiction

Volumn 100, Issue SUPPL. 1, 2005, Pages 78-90

  Shoptaw, Steven ^a   Watson, Donnie W ^b   Reiber, Chris ^a   Rawson, Richard A ^a   Montgomery, Margaret A ^c   Majewska, Maria D ^c   Ling, Walter ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FRIENDS RESEARCH INSTITUTE   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Cabergoline; Cocaine; Hydergine; Levodopa carbidopa; Out patient

Indexed keywords

BENZOYLECGONINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; COCAINE; DIHYDROERGOTOXINE MESILATE; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG METABOLITE; PLACEBO;

ADDICTION; ADULT; ARTICLE; BEHAVIOR THERAPY; BRIEF SUBSTANCE RATING SCALE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COCAINE DEPENDENCE; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATIENT COMPLIANCE; PATIENT COUNSELING; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCREENING; SELF REPORT; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; CARBIDOPA; COCAINE-RELATED DISORDERS; DOPAMINE AGENTS; ERGOLINES; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 14944382305     PISSN: 09652140     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2005.00991.x     Document Type: Article

References (45)

1. Ahlskog, J. E., Wright, K. F., Muenter, M. D. & Adler, C. H. (1996) Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose-responses and duration of effect. Clinical Neuropharmacology, 19, 202-212.
2. Brief, D., Bollinger, A., Horton, G. & LoCastro, J. S. (1998) Relapse Prevention Treatment for Cocaine Addiction: the RPT-C Manual. Bethesda, MD: Medication Development Division, National Institute on Drug Abuse.
3. Bruss, G. S., Gruenberg, A. M., Goldsteinm, R. D. & Barber, J. P. (1994) Hamilton Anxiety Rating Scale Interview guide: joint interview and test-retest methods for interrater reliability. Psychiatry Research, 53, 191-202.
4. Calabresi, P., Stefani, A., Mercuri, N. B. & Bernardi, G. (1989) Acetylcholine-dopamine balance in striatum: is it still a target for antiparkinsonian therapy? EXS, 57, 315-321.
5. Calon, F., Morissette, M., Goulet, M., Grondin, R., Blanchet, P. J., Bedard, P. J. & DiPaolo, T. (2000) 125I-CGP 64213 binding to GABA(B) receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments. Experimental Neurology, 163, 191-199.
6. Chen, J., Paredes, W., Lowinson, J. H. & Gardner, E. L. (1990) Delta 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex. European Journal of Pharmacology, 190, 259-262.
7. Colao, A., DiSarno, A., Marzullo, P., DiSomma, C., Cerbone, G., Landi, M. L., Faggiano, A., Merola, B. & Lombardi, G. (2000) New medical approaches in pituitary adenomas. Hormone Research, 53, 76-87.
8. Cotzias, G., Papavasiliou, P. & Gellene, R. (1969) Modification of parkinsonism-chronic treatment with L-dopa. New England Journal of Medicine, 280, 337-345.
9. Dackis, C. A., Gold, M. S., Sweeney, D. R., Buron, J. P. Jr & Climko, R. (1987) Single-dose bromocriptine reverses cocaine craving. Psychiatry Research, 20, 261-264.
10. Datta, K. D., Evenson, R. C., Gannon, P. J. & Dick, E. P. (1987) Efficacy of oral hydergine (ergoloid mesylates) in alcohol related encephalopathy. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 11, 87-90.
11. de Lima, M. S., de Oliveira Soares, B. G., Reisser, A. A. & Farrell. M. (2002) Pharmacological treatment of cocaine dependence: A systematic review. Addiction, 97: 931-949.
12. Diggle, P. J., Liang, K. Y. & Zeger, S. L. (1994) Analysis of Longitudinal Data. Oxford, UK: Oxford University Press.
13. Dworkin, S. I., Goeders, N. E. & Smith, J. E. (1986) The reinforcing and rate effects of intracranial dopamine administration. NIDA Research Monograph, 67, 242-248.
14. Dworkin, S. I., Guerin, G. F., Goeders, N. E. & Smith, J. E. (1988) Kainic acid lesions of the nucleus accumbens selectively attenuate morphine self-administration. Pharmacology, Biochemistry and Behavior, 29, 175-181.
15. Goldstein, M. (1985) Ergot alkaloids and central monoaminergic receptors. Journal de Pharmacologie, 16, 19-24.
16. Hamilton, M. (1967) Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology, 6, 278-296.
17. Hoebel, B. G., Monaco, A. P., Hernandez, L., Aulisi, E. F., Stanley, B. G. & Lenard, L. (1983) Self-injection of amphetamine directly into the brain. Psychopharmacology, 81, 158-163.
18. Huber, F., Koberle, S., Prestele, H. & Spiegel, R. (1986) Effects of long-term ergoloid mesylates ('Hydergine') administration in healthy pensioners: 5-year results. Current Medical Research and Opinion, 10, 256-279.
19. Hutton, J. T., Koller, W. C., Ahlskog, J. E., Pahwa, R., Hurtig, H. I., Stern, M. B., Hiner, B. C., Lieberman, A., Pfeiffer, R. F., Rodnitzky, R. L., Waters, C. H., Muenter, M. D., Adler, C. H. & Morris, J. L. (1996) Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology, 46, 1062-1065.
20. Imperato, A. & DiChiara, G. (1986) Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. Journal of Pharmacology and Experimental Therapeutics, 239, 219-228.
21. Inzelberg, R., Nisipeanu, P., Rabey, M. J. & Korczyn, A. D. (1995) Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease. Movement Disorders, 10, 604-607.
22. Jentsch, J. D. & Taylor, J. R. (1999) Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology, 146, 373-390.
23. Johnson, S. W. & North, R. A. (1992) Two types of neurone in the rat ventral tegmental area and their synaptic inputs. Journal of Physiology, 450, 455-468.
24. Leone, P., Pocock, D. & Wise, R. A. (1991) Morphine-dopamine interaction: ventral tegemental morphine increases nucleus accumbens dopamine release. Pharmacology, Biochemistry and Behavior, 39, 469-472.
25. Ling, W. & Shoptaw, S. (1997) Integration of research in pharmacotherapy for substance abuse: where are we? Where are we going? Journal of Addictive Diseases, 16, 83-102.
26. Ling, W., Shoptaw, S., Wesson, D., Rawson, R. A., Compton, M. & Klett, C. J. (1997) Treatment effectiveness score as an outcome measure in clinical trials. NIDA Research Monograph, 175, 208-220.
27. Markstein, R. (1985) Hydergine: interaction with the neurotransmitter systems in the central nervous system. Journal de Pharmacologie, 16, 1-17.
28. McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H. & Argeriou, M. (1992) The fifth edition of the Addiction Severity Index. Journal of Substance Abuse Treatment, 9, 199-213.
29. Mezinskis, J., Dryenforth, S., Goldsmith, R. & Cohen, Somoza, E. (1998) Craving and withdrawal symptoms for various drugs of abuse. Psychiatric Annals, 28, 577-583.
30. Muratori, M., Arosio, M., Gambino, G., Romano, C., Biella, O. & Faglia, G. (1997) Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. Journal of Endocrinological Investigation, 20, 537-546.
31. Nagasawa, H., Kogure, K., Kawashima, K., Ido, T., Itoh, M. & Hatazawa, J. (1990) Effects of co-dergocrine mesylate (Hydergine) in multi-infarct dementia as evaluated by positron emission tomography. Tohoku Journal of Experimental Medicine, 162, 225-233.
32. Navaline, H. A., Snider, E. C., Petro, C. J., Tobin, D., Metzger, D., Alterman, A. I. & Woody, G. E. (1994) Preparations for AIDS vaccine trials. An automated version of the Risk Assessment Battery (RAB): Enhancing the assessment of risk behaviors. AIDS Research on Human Retroviruses, 10, 5281-5283.
33. Nisell, M., Nomikos, G. G. & Svensson, T. H. (1994) Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse, 16, 36-44.
34. Pontieri, F. E., Tanda, G., Orzi, F. & DiChiara, G. (1996) Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature, 382, 255-257.
35. Preston, K. L., Silverman, K., Schuster, C. R. & Cove, E. J. (1997) Use of quantitative urinalysis in monitoring cocaine use. NIDA Research Monograph, 175, 253-263.
36. Rouy, J. M., Douillon, A. M., Compan, B. & Wolmark, Y. (1989) Ergoloid mesylates ('Hydergine') in the treatment of mental deterioration in the elderly: a 6-month double-blind, placebo-controlled trial. Current Medical Research and Opinion, 11, 380-389.
37. Schneider, L. S. & Olin, J. T. (1994) Overview of clinical trials of hydergine in dementia. Archives of Neurology, 51, 787-798.
38. Self, D. W. & Nestler, E. J. (1995) Molecular mechanisms of drug reinforcement and addiction. Annual Review of Neuroscience, 18, 463-495.
39. Spitzer, R. L., Williams, J. B., Gibbon, M. & First, M. B. (1995) The Structured Clinical Interview for DSM-IV. Washington. DC: American Psychiatric Press.
40. Steiger, M. J., El-Debas, T., Anderson, T., Findley, L. J. & Marsden, C. D. (1996) Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. Journal of Neurology, 243, 68-72.
41. Thienhaus, O. J., Wheeler, B. G., Simon, S., Zemlan, F. P. & Hartford, J. T. (1987) A controlled double-blind study of high-dose dihydroergotoxine mesylate (Hydergine) in mild dementia. Journal of the American Geriatric Society, 35, 219-223.
42. Webster, J., (1999) Dopamine agonist therapy in hyperprolactinemia. Journal of Reproductive Medicine, 44, 1105-1110.
43. Webster, J., Piscitelli, G., Polli, A., D'Alberton, A., Falsetti, L., Ferarri, C., Fioretti, P., Giordano, G., L'Hermite, M., Ciccarelli, E. et al. (1993) The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group. Clinical Endocrinology, 39, 323-329.
44. Webster, J., Piscitelli, G., Polli, A., Ferrari, C. I., Ismail, I. & Scanlon, M. F. (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. New England Journal of Medicine, 331, 904-909.
45. Wolfsohn, R., Sanfilipo, M. & Angrist, B. (1993) A placebo-controlled trial of L-dopa/carbidopa in early cocaine abstinence. Neuropsychopharmacology, 9, 49-53.